Rybrevant 50 mg/ml Injection 7 ml

Rybrevant 50 mg/ml Injection 7 ml is a monoclonal bispecific antibody primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, growing more slowly than small cell lung cancer. It has several subtypes, including adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma. Symptoms often include coughing, chest pain, and shortness of breath.

Rybrevant 50 mg/ml Injection 7 ml contains amivantamab, which targets and inhibits the activity of EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor), both of which are involved in cancer cell growth and spread. Rybrevant 50 mg/ml Injection 7 ml disrupts pathways that promote cancer cell growth, helping to reduce tumor size and slow disease progression.

In some cases, this medicine may cause side effects like rash, itching, muscle/joint pain, edema, shortness of breath, cough, constipation, changes in vision, chest discomfort, fever, and flushing. The majority of these side effects may not require medical treatment and will subside with time. However, if the side effects persist or worsen, see a doctor.

Rybrevant 50 mg/ml Injection 7 ml should not be received if you are allergic to it. Before starting treatment with Rybrevant 50 mg/ml Injection 7 ml, inform your doctor about any other medications or herbal products you are taking. Brief your medical history to the doctor in advance if you have a history of lung or breathing issues, skin disorders, eye problems, and liver/kidney impairment. Rybrevant 50 mg/ml Injection 7 ml is not recommended for use during pregnancy and breastfeeding. Also, it is not recommended for children, as its safety and efficacy have not been established.

Rybrevant 50 mg/ml Injection 7 ml is administered by a healthcare professional; do not self-administer.

Rybrevant 50 mg/ml Injection 7 ml is used to treat non-small cell lung cancer (NSCLC). It specifically targets both the EGFR and MET receptors, which are involved in cancer cell development, resulting in a more precise treatment with fewer side effects than conventional chemotherapy. As a monoclonal antibody, it binds to specific cancer cell receptors, minimizing off-target effects. It slows disease progression and shrinks tumors by disrupting mechanisms that drive cancer cell proliferation. Rybrevant 50 mg/ml Injection 7 ml may also be effective for patients with specific mutations or who have developed resistance to other EGFR-targeted treatments.

Brief your medical history to the doctor in advance if you have a history of lung or breathing issues, skin disorders, eye problems, and liver/kidney impairment. Individuals with pre-existing lung conditions should use Rybrevant 50 mg/ml Injection 7 ml with caution, as it may worsen lung symptoms or lead to interstitial lung disease (ILD). Rybrevant 50 mg/ml Injection 7 ml can cause fetal harm, so it should be avoided during pregnancy. Avoid breastfeeding during treatment with Rybrevant 50 mg/ml Injection 7 ml and for 3 months after the last dose. Rybrevant 50 mg/ml Injection 7 ml is not recommended for children, as its safety and efficacy have not been established. Seek medical attention if you experience symptoms of lung problems (shortness of breath, cough, or fever), skin problems (rash, itching or dry skin), or eye problems (eye pain, dry eyes, blurred vision, redness, changes in vision, itching, excessive tearing or sensitivity to light).